AstraZeneca secures Japanese distribution for FluMist

AstraZeneca and Daiichi Sankyo make FluMist license agreement
AstraZeneca and Daiichi Sankyo make FluMist license agreement | Courtesy of biology.usf.edu
AstraZeneca recently announced that MedImmune, its global biologics research and development branch, has agreed to give Daiichi Sankyo Co. Ltd. the exclusive license to create and sell Flumist Quadrivalent within Japan.

FluMist Quadrivalent, a live attenuated influenza vaccine, is given to people through a nasal spray. The vaccine has four protective strains of the flu virus. During the 2014 and 2015 flu season, Japanese children were included in a Phase III study for FluMist to determine its safety and effectiveness. Now, a regulatory submission is in the preparation phase in Japan.

"We're pleased to enter into this agreement with Daiichi Sankyo, whose specific expertise in developing and commercializing innovative vaccines will help ensure we bring FluMist Quadrivalent to as many children as possible in Japan,” Marc Dunoyer, AstraZeneca's senior executive team member responsible for Japan, said.

According to the agreement, Daiichi Sankyo will give AstraZeneca an upfront payment with following milestones as well as sales-related payments after the vaccine is launched.

"We are proud to be able to deliver, once approved, FluMist Quadrivalent to Japanese children and adolescents and to make a contribution to public health by protecting people from influenza,” Takeshi Ogita, head of Daiichi Sankyo's Vaccine Business Unit, said.

AstraZeneca operates in over 100 countries, with its medicines used by millions of patients worldwide.

Organizations in this Story

AstraZeneca Pharmaceuticals LP

Want to get notified whenever we write about AstraZeneca Pharmaceuticals LP ?
Next time we write about AstraZeneca Pharmaceuticals LP, we'll email you a link to the story. You may edit your settings or unsubscribe at any time.